How US-UK drug deal will benefit patients | Letters

Many new medicines have reached NHS patients as a result of the government’s reformed pricing arrangements, writes Richard Torbett. Plus a letter from Nick Hoile The suggestion that the US-UK pharmaceutical agreement will result in excess deaths is alarmist and relies on a heavily critiqued approach to modelling how much the NHS can spend to generate health (US-UK drug deal could result in 229,000 excess deaths in England, analysis suggests, 1 July). It is underpinned by incomplete data. In j...

By Guardian Staff